{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T07:12:05Z","timestamp":1793949125716,"version":"4.8.0"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,17]],"date-time":"2019-10-17T00:00:00Z","timestamp":1571270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005492","name":"Stanford University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005492","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.ijpddr.2019.10.003","type":"journal-article","created":{"date-parts":[[2019,10,22]],"date-time":"2019-10-22T12:08:56Z","timestamp":1571746136000},"page":"80-94","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia"],"prefix":"10.1016","volume":"11","author":[{"given":"Monica M.","family":"Kangussu-Marcolino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gretchen M.","family":"Ehrenkaufer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjan","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Upinder","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpddr.2019.10.003_bib1","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.3201\/eid1411.070854","article-title":"Successful treatment of disseminated Acanthamoeba sp. infection with miltefosine","volume":"14","author":"Aichelburg","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib2","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0002973","article-title":"Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis","volume":"8","author":"Andrade","year":"2014","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib3","series-title":"Murine in Vivo Tumor Models for Investigating the Anticancer Potential of Natural and Synthetic Compounds","first-page":"102","author":"Atzberger","year":"2018"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/ICL.0b013e31802b64c1","article-title":"Updates in Acanthamoeba keratitis","volume":"33","author":"Awwad","year":"2007","journal-title":"Eye Contact Lens"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1440-1827.2012.02816.x","article-title":"Autopsy case of amebic granulomatous meningoencephalitis caused by Balamuthia mandrillaris in Japan","volume":"62","author":"Bando","year":"2012","journal-title":"Pathol. Int."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib6","series-title":"102nd Annual Meeting of the American Association for Cancer Research Poster Presentation","article-title":"Abstract 2615: antitumor activity of a dual PI3K and HDAC inhibitor in hematologic cancer models","author":"Bao","year":"2011"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib7","doi-asserted-by":"crossref","first-page":"5155","DOI":"10.1016\/j.bmcl.2015.10.002","article-title":"Discovery of 1-(4-(5-(5-amino-6-(5-tert-butyl-1,3,4-oxadiazol-2-yl)pyrazin-2-yl)-1-ethyl-1,2,4 -triazol-3-yl)piperidin-1-yl)-3-hydroxypropan-1-one (AZD8835): a potent and selective inhibitor of PI3Kalpha and PI3Kdelta for the treatment of cancers","volume":"25","author":"Barlaam","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib8","doi-asserted-by":"crossref","first-page":"7524","DOI":"10.1021\/acs.jmedchem.7b00930","article-title":"5-(4,6-Dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine (PQR309), a potent, brain-penetrant, orally bioavailable, pan-class I PI3K\/mTOR inhibitor as clinical candidate in oncology","volume":"60","author":"Beaufils","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib9","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1128\/JCM.43.4.1689-1693.2005","article-title":"Identification and distribution of Acanthamoeba species genotypes associated with nonkeratitis infections","volume":"43","author":"Booton","year":"2005","journal-title":"J. Clin. Microbiol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib10","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s10637-013-0062-5","article-title":"Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer","volume":"32","author":"Britten","year":"2014","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib11","author":"Calibr"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib12","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.1093\/jpids\/piu103","article-title":"Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937-2013","volume":"4","author":"Capewell","year":"2015","journal-title":"J. Pediatr. Infect. Dis. Soc."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib13","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-16","article-title":"Phase I clinical trial results of auranofin, a novel antiparasitic agent","volume":"61","author":"Capparelli","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib14","author":"CDC"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib15","first-page":"666","article-title":"Centers for Disease, Control and Prevention. Investigational drug available directly from CDC for the treatment of infections with free-living amebae","volume":"62","author":"CDC","year":"2013","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib16","author":"CDC"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib17","unstructured":"ClinicalTrials.gov, ClinicalTrials.gov is a database of privately and publicly funded clinical studies conducted around the world. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib18","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1093\/infdis\/jiy622","article-title":"Phenotypic screens reveal posaconazole as a rapidly acting amebicidal combination partner for treatment of primary amoebic meningoencephalitis","volume":"219","author":"Colon","year":"2019","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib19","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.clml.2015.02.017","article-title":"A phase I study of midostaurin and azacitidine in relapsed and elderly AML patients","volume":"15","author":"Cooper","year":"2015","journal-title":"Clin. Lymphoma, Myeloma & Leukemia"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib20","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/cid\/civ1021","article-title":"Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis: report of 1 fatal and 1 surviving case","volume":"62","author":"Cope","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006104","article-title":"CYP51 is an essential drug target for the treatment of primary amoebic meningoencephalitis (PAM)","volume":"11","author":"Debnath","year":"2017","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib22","doi-asserted-by":"crossref","first-page":"66","DOI":"10.4161\/gmic.22596","article-title":"Reprofiled drug targets ancient protozoans: drug discovery for parasitic diarrheal diseases","volume":"4","author":"Debnath","year":"2013","journal-title":"Gut Microb."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib23","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3389\/fmicb.2018.00414","article-title":"In vitro efficacy of Ebselen and BAY 11-7082 against Naegleria fowleri","volume":"9","author":"Debnath","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib24","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Debnath","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib25","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1128\/AAC.00643-12","article-title":"Corifungin, a new drug lead against Naegleria, identified from a high-throughput screen","volume":"56","author":"Debnath","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib26","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/AAC.02254-13","article-title":"In vitro efficacy of corifungin against Acanthamoeba castellanii trophozoites and cysts","volume":"58","author":"Debnath","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib27","doi-asserted-by":"crossref","first-page":"e1297","DOI":"10.1371\/journal.pntd.0001297","article-title":"The susceptibility of trypanosomatid pathogens to PI3\/mTOR kinase inhibitors affords a new opportunity for drug repurposing","volume":"5","author":"Diaz-Gonzalez","year":"2011","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jhealeco.2016.01.012","article-title":"Innovation in the pharmaceutical industry: new estimates of R&D costs","volume":"47","author":"DiMasi","year":"2016","journal-title":"J. Health Econ."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib29","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1128\/AAC.10.2.370","article-title":"In vitro susceptibility of pathogenic Naegleria and Acanthamoeba speicies to a variety of therapeutic agents","volume":"10","author":"Duma","year":"1976","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib30","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1099\/mic.0.27218-0","article-title":"Balamuthia mandrillaris from soil samples","volume":"150","author":"Dunnebacke","year":"2004","journal-title":"Microbiology"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib31","doi-asserted-by":"crossref","first-page":"13395","DOI":"10.1074\/jbc.M700498200","article-title":"The rapamycin-binding domain of the protein kinase mammalian target of rapamycin is a destabilizing domain","volume":"282","author":"Edwards","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib113","unstructured":"Ehrenkaufer, G., Li, P., Stebbens, E.E., Kangussu-Marcolino, M.M., Debnath, A., White, C.V., Moser, M.S., DeRisi, J., Gisselberg, J., Yeh, E., Wang, S.C., Company, A.H., Monti, L., Caffrey, C.R., Huston, C.D., Bo, W., Singh, U., manuscript in preparation. Identification of anisomycin, prodigiosin and obatoclax as compounds with broad-spectrum anti-parasitic activity."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib32","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/00007691-199206000-00013","article-title":"Determination of plicamycin in plasma by radioimmunoassay","volume":"14","author":"Fang","year":"1992","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib33","author":"FDA"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib34","author":"FDA"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib35","author":"FDA"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib36","unstructured":"FDA, Orphan drug listing. US food and drug administration. Search orphan drug designations and approvals. https:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib37","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/onc.2008.246","article-title":"Drug discovery approaches targeting the PI3K\/Akt pathway in cancer","volume":"27","author":"Garcia-Echeverria","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib38","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1038\/leu.2011.218","article-title":"TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties","volume":"26","author":"Goh","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib39","series-title":"Goodman & Gilman's the Pharmacological Basis of Therapeutics","author":"Goodman","year":"1996"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib40","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1535-7163.MCT-12-0466","article-title":"VS-5584, a novel and highly selective PI3K\/mTOR kinase inhibitor for the treatment of cancer","volume":"12","author":"Hart","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1021\/acsmedchemlett.6b00005","article-title":"Discovery of clinical development candidate GDC-0084, a brain penetrant inhibitor of PI3K and mTOR","volume":"7","author":"Heffron","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib42","doi-asserted-by":"crossref","first-page":"e0169485","DOI":"10.1371\/journal.pone.0169485","article-title":"Pre-clinical study of panobinostat in xenograft and genetically engineered murine diffuse intrinsic pontine glioma models","volume":"12","author":"Hennika","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib43","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3109\/10428194.2014.1001986","article-title":"Phase I dose escalation study of lestaurtinib in patients with myelofibrosis","volume":"56","author":"Hexner","year":"2015","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib44","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.3052.3052","article-title":"TG02, an oral CDK9-inhibitor, in combination with carfilzomib demonstrated objective responses in carfilzomib refractory multiple myeloma patients","volume":"126","author":"Hofmeister","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib45","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1158\/1078-0432.CCR-11-2703","article-title":"A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas","volume":"18","author":"Hong","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib46","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijantimicag.2016.09.020","article-title":"Auranofin inactivates Trichomonas vaginalis thioredoxin reductase and is effective against trichomonads in vitro and in vivo","volume":"48","author":"Hopper","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib47","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nature10912","article-title":"The translational landscape of mTOR signalling steers cancer initiation and metastasis","volume":"485","author":"Hsieh","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib48","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00726-011-0997-9","article-title":"A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition","volume":"42","author":"Ilari","year":"2012","journal-title":"Amino Acids"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib49","doi-asserted-by":"crossref","first-page":"10750","DOI":"10.1073\/pnas.1810137115","article-title":"The ReFRAME library as a comprehensive drug repurposing library and its application to the treatment of cryptosporidiosis","volume":"115","author":"Janes","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.5858\/2004-128-466-BMMIAI","article-title":"Balamuthia mandrillaris meningoencephalitis in an immunocompetent patient: an unusual clinical course and a favorable outcome","volume":"128","author":"Jung","year":"2004","journal-title":"Arch. Pathol. Lab Med."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib114","unstructured":"Kangussu-Marcolino, M.M., Ehrenkaufer, G.M., Chen, E., Singh, U., manuscript in preparation. FDA approved and advanced clinically tested compounds identified at the ReFRAME library as potent compounds against Entamoeba histolytica."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib51","doi-asserted-by":"crossref","first-page":"e0006701","DOI":"10.1371\/journal.pntd.0006701","article-title":"Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin","volume":"12","author":"Khadir","year":"2018","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/j.1574-6976.2006.00023.x","article-title":"Acanthamoeba: biology and increasing importance in human health","volume":"30","author":"Khan","year":"2006","journal-title":"FEMS Microbiol. Rev."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1021\/ml900028r","article-title":"Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin","volume":"1","author":"Knight","year":"2010","journal-title":"ACS Med. Chem. Lett."},{"issue":"5","key":"10.1016\/j.ijpddr.2019.10.003_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4132\/jptm.2019.05.14","article-title":"Amoebic encephalitis caused by Balamuthia mandrillaris","volume":"53","author":"Kum","year":"2019","journal-title":"J. Pathol. Transl. Med."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib55","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.diagmicrobio.2015.04.007","article-title":"Novel culture medium for the axenic growth of Balamuthia mandrillaris","volume":"82","author":"Lares-Jimenez","year":"2015","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib56","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02051-18","article-title":"Functional assessment of 2,177 U.S. And international drugs identifies the quinoline nitroxoline as a potent amoebicidal agent against the pathogen Balamuthia mandrillaris","volume":"9","author":"Laurie","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib57","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/neuonc\/nou350","article-title":"Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma","volume":"17","author":"Lee","year":"2015","journal-title":"Neuro Oncol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib58","doi-asserted-by":"crossref","first-page":"e744","DOI":"10.1542\/peds.2014-2292","article-title":"Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis","volume":"135","author":"Linam","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib59","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.lfs.2013.04.005","article-title":"Novel protective properties of auranofin: inhibition of human astrocyte cytotoxic secretions and direct neuroprotection","volume":"92","author":"Madeira","year":"2013","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib60","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s00436-004-1106-8","article-title":"Different effects of cytochalasins on the growth and differentiation of Entamoeba invadens","volume":"93","author":"Makioka","year":"2004","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib62","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0035130","article-title":"Modulation of the activity of Sp transcription factors by mithramycin analogues as a new strategy for treatment of metastatic prostate cancer","volume":"7","author":"Malek","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib63","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1093\/annonc\/mds011","article-title":"Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors","volume":"23","author":"Markman","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib64","doi-asserted-by":"crossref","first-page":"5981","DOI":"10.1158\/1078-0432.CCR-17-0725","article-title":"A first-time-in-human study of GSK2636771, a phosphoinositide 3 kinase beta-selective inhibitor, in patients with advanced solid tumors","volume":"23","author":"Mateo","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000291","article-title":"Phase I study of the investigational oral mTORC1\/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours","volume":"3","author":"Moore","year":"2018","journal-title":"ESMO Open"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib66","series-title":"Patients with High-Grade Glioma, Poster Presentation","article-title":"Clinical pharmacokinetics and brain penetration of GDC-0084, an oral PI3K\/mTOR inhibitor","author":"Morrissey","year":"2016"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib67","doi-asserted-by":"crossref","first-page":"5599","DOI":"10.1021\/acs.jmedchem.5b00627","article-title":"Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115","volume":"58","author":"Mortensen","year":"2015","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib68","doi-asserted-by":"crossref","first-page":"13891","DOI":"10.1038\/srep13891","article-title":"High-throughput matrix screening identifies synergistic and antagonistic antimalarial drug combinations","volume":"5","author":"Mott","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib69","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jcpt.12082","article-title":"Effects of food on the pharmacokinetics of ponatinib in healthy subjects","volume":"38","author":"Narasimhan","year":"2013","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib70","unstructured":"NCT00084422, N2001-03: CEP-701 in Treating Young Patients with Recurrent or Refractory High-Risk Neuroblastoma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib71","unstructured":"NCT00557193, Combination Chemotherapy with or without Lestaurtinib in Treating Younger Patients with Newly Diagnosed Acute Lymphoblastic Leukemia. . ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib72","unstructured":"NCT02133183, Sapanisertib before and after Surgery in Treating Patients with Recurrent Glioblastoma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib73","unstructured":"NCT02942264, TG02 plus dose-dense or metronomic temozolomide followed by randomized phase II trial of TG02 plus temozolomide versus temozolomide alone in adults with recurrent anaplastic astrocytoma and glioblastoma. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib74","unstructured":"NCT03740100, Single-arm Study with Bimiralisib in Patients with HNSCC Harboring NOTCH1 Loss of Function Mutations (HNSCC). ClinicalTrials.Gov [Internet]. Bethesda (MD): National Library of Medicine (US)."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib75","unstructured":"NCT03765983, GDC-0084 in Combination with Trastuzumab for Patients with HER2-Positive Breast Cancer Brain Metastases."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib76","doi-asserted-by":"crossref","first-page":"4597","DOI":"10.1021\/jm4003632","volume":"56","author":"Ndubaku","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib77","series-title":"Farydak (Panobinostat), Capsules, Product Leaflet","author":"Novartis","year":"2016"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1254\/jphs.13R02CP","article-title":"Mithramycin, an agent for developing new therapeutic drugs for neurodegenerative diseases","volume":"122","author":"Osada","year":"2013","journal-title":"J. Pharmacol. Sci."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib79","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2174\/187231212800229336","article-title":"Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK\/JAK2\/FLT3 inhibitor","volume":"6","author":"Pasha","year":"2012","journal-title":"Drug Metab. Lett."},{"issue":"4","key":"10.1016\/j.ijpddr.2019.10.003_bib80","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/jeu.12706","article-title":"Antiparasitic activity of auranofin against pathogenic Naegleria fowleri","volume":"66","author":"Peroutka-Bigus","year":"2018","journal-title":"J. Eukaryot. Microbiol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib81","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s00436-011-2515-0","article-title":"Efficacy of miltefosine for topical treatment of Acanthamoeba keratitis in Syrian hamsters","volume":"110","author":"Polat","year":"2012","journal-title":"Parasitol. Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib82","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1158\/1078-0432.CCR-12-0055","article-title":"Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling","volume":"18","author":"Qian","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib83","first-page":"84","article-title":"Farydak (panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma","volume":"9","author":"Raedler","year":"2016","journal-title":"Am. Health Drug Benefit."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib84","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1167\/tvst.3.5.1","article-title":"Latrunculin B reduces intraocular pressure in human ocular hypertension and primary open-angle glaucoma","volume":"3","author":"Rasmussen","year":"2014","journal-title":"Transl. Vis. Sci. Technol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib85","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.2147\/DDDT.S193889","article-title":"Pharmacokinetics and pharmacodynamics of the novel Nrf2 activator omaveloxolone in primates","volume":"13","author":"Reisman","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib86","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1097\/00003086-197709000-00012","article-title":"Treatment of Paget's disease of bone with mithramycin","author":"Ryan","year":"1977","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib87","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1124\/dmd.116.071423","article-title":"Brain distribution and efficacy of the brain penetrant PI3K inhibitor GDC-0084 in orthotopic mouse models of human glioblastoma","volume":"44","author":"Salphati","year":"2016","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib88","first-page":"4375","article-title":"Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin","volume":"58","author":"Sarkaria","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib89","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0041-1345(98)00587-9","article-title":"Chemical modification of rapamycin: the discovery of SDZ RAD","volume":"30","author":"Sedrani","year":"1998","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib90","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1158\/0008-5472.CAN-07-6487","article-title":"A new pharmacologic action of CCI-779 involves FKBP12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis","volume":"68","author":"Shor","year":"2008","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib91","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4103\/2229-5070.149888","article-title":"Balamuthia mandrillaris: morphology, biology, and virulence","volume":"5","author":"Siddiqui","year":"2015","journal-title":"Tropenmed. Parasitol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib92","first-page":"258","article-title":"[Parameters of the toxic action of antibiotic derivatives of aureolic acid in acute and subchronic experiments]","volume":"21","author":"Solov'ev","year":"1976","journal-title":"Antibiotiki"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib93","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2013.06.017","article-title":"mTOR kinase inhibitors as potential cancer therapeutic drugs","volume":"340","author":"Sun","year":"2013","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib94","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/jm2009327","article-title":"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer","volume":"54","author":"Sutherlin","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40262-018-0679-9","article-title":"Clinical pharmacokinetics and pharmacodynamics of bortezomib","volume":"58","author":"Tan","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib96","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.01675-12","article-title":"A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia","volume":"57","author":"Tejman-Yarden","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib97","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.radonc.2017.08.001","article-title":"Antitumor activity of the dual PI3K\/MTOR inhibitor, PF-04691502, in combination with radiation in head and neck cancer","volume":"124","author":"Tonlaar","year":"2017","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib98","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s40262-017-0565-x","article-title":"Clinical pharmacokinetics and pharmacodynamics of panobinostat","volume":"57","author":"Van Veggel","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib99","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib100","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1158\/1078-0432.CCR-13-0312","article-title":"A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors","volume":"19","author":"Venugopal","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib101","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/QCO.0b013e32833ed78b","article-title":"Amebic meningoencephalitides and keratitis: challenges in diagnosis and treatment","volume":"23","author":"Visvesvara","year":"2010","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib102","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1574-695X.2007.00232.x","article-title":"Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea","volume":"50","author":"Visvesvara","year":"2007","journal-title":"FEMS Immunol. Med. Microbiol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib103","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1128\/AAC.02147-13","article-title":"Urinary concentrations and antibacterial activities of nitroxoline at 250 milligrams versus trimethoprim at 200 milligrams against uropathogens in healthy volunteers","volume":"58","author":"Wagenlehner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib104","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3171\/jns.1976.44.6.0655","article-title":"Evaluation of mithramycin in the treatment of anaplastic gliomas","volume":"44","author":"Walker","year":"1976","journal-title":"J. Neurosurg."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib105","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.2012","article-title":"A first-in-human phase 1 study to evaluate the brain-penetrant PI3K\/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma","volume":"34","author":"Wen","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib106","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejca.2018.03.012","article-title":"First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1\/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67\/13)","volume":"96","author":"Wicki","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib107","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12122","article-title":"mTOR kinase structure, mechanism and regulation","volume":"497","author":"Yang","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.ijpddr.2019.10.003_bib109","doi-asserted-by":"crossref","first-page":"25846","DOI":"10.1016\/S0021-9258(19)74466-4","article-title":"Inhibition of histamine secretion by wortmannin through the blockade of phosphatidylinositol 3-kinase in RBL-2H3 cells","volume":"268","author":"Yano","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib110","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1017\/S0950268809991014","article-title":"The epidemiology of primary amoebic meningoencephalitis in the USA, 1962-2008","volume":"138","author":"Yoder","year":"2010","journal-title":"Epidemiol. Infect."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib111","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1158\/1535-7163.MCT-11-0185","article-title":"PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity","volume":"10","author":"Yuan","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ijpddr.2019.10.003_bib112","first-page":"15","article-title":"mTOR inhibitors at a glance","volume":"7","author":"Zheng","year":"2015","journal-title":"Mol. Cell. Pharmacol."}],"container-title":["International Journal for Parasitology: Drugs and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719301022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211320719301022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:50:26Z","timestamp":1761922226000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211320719301022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":114,"alternative-id":["S2211320719301022"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.10.003","relation":{},"ISSN":["2211-3207"],"issn-type":[{"value":"2211-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of plicamycin, TG02, panobinostat, lestaurtinib, and GDC-0084 as promising compounds for the treatment of central nervous system infections caused by the free-living amebae Naegleria, Acanthamoeba and Balamuthia","name":"articletitle","label":"Article Title"},{"value":"International Journal for Parasitology: Drugs and Drug Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpddr.2019.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology.","name":"copyright","label":"Copyright"}]}}